Coumadin Blood Thinner Lawsuits Filed Against GlaxoSmithKline – More to Come?

The Crohn’s Disease and Murad Corporation brought the first successful coumadin blood thinner lawsuit against GlaxoSmithKline, the primary manufacturer of the drug. The case was filed in the Southern District of Florida, and was later moved to the Eastern District of California. The plaintiffs filed a claim for damages against GlaxoSmithKline, alleging that the company did not provide warnings about the risks of taking this particular drug, and did not offer adequate warnings prior to introducing it into the marketplace. In essence, plaintiffs were asking for damages due to negligence on the part of GlaxoSmithKline.

The recent Crohn’s Disease and Murad lawsuit updates the prior cases and adds new plaintiffs to the mix.

One of the plaintiffs in the prior litigation, identified as Issues Manager for Clinical Development at J.R. Moss, was unfortunately unable to join her husband in the United States due to her inability to obtain a visa. Ms. Moss was due to begin working on a new blood thinning treatment for her husband, when suddenly her visa was denied. As a result of this unfortunate circumstance, Ms. Moss pursued her lawsuit on her own, seeking damages for her loss of income, emotional suffering, and various other injuries.

A few months later, a new plaintiff filed suit in the Southern District of Florida, claiming that his wife had died after suffering from severe bleeding events, consistent with having blood thinners.

This second case is different from the prior complaints, as it relates to the time frame of the death, which occurred early last year. This second case is similar to the first, as both plaintiffs’ claims center on the bleeding events that occurred during early 2021. However, in the second case, there are new witnesses joining the fray. It is believed that more than one blood thinner could have been administered to the plaintiff’s wife during these early events. These new witnesses bring hope to plaintiffs’ litigation, as they suggest that there may be numerous class-action lawsuits against GlaxoSmithKline, the company responsible for producing the products used in the prior lawsuits.

The plaintiffs’ second claim is also similar to the first: that their wife suffered a bleeding risk due to the use of blood thinners.

The plaintiffs argue that GlaxoSmithKline did not adequately inform the manufacture of its afib products that such a risk was present; thus, allowing the product to be improperly sold to consumers. Moreover, GlaxoSmithKline’s policies for dealing with blood thinners were inadequate and did not adequately notify plaintiffs of the significant health and safety risks associated with its products. Additionally, the policy instructed that employees using blood thinners should seek further medical attention from their personal doctor, or else should contact the manufacturer for assistance. No such instruction was provided to plaintiffs, as is characteristic of many blood thinners.

In late December of last year, we reported on a new court case in which the plaintiff’s attorneys alleged that GlaxoSmithKline manufactured a product which resulted in dire side effects for one of its workers; thus, bringing the lawsuit status of the case to a new level of uncertainty.

The recent claim against GlaxoSmithKline also brought to light yet another unfortunate consequence of the use of anticoagulant medicines in medicine. As we previously reported on this case in our previous article, the U.S. Food and Drug Administration (FDA) had recently approved the use of warfarin for the treatment of hemorrhagic stroke, but it is unknown if it will ever be approved for use in the treatment of patients with bendable ulcers. As of this writing, the pending approval by the FDA for warfarin is still classified as an Investigational New Drug, and therefore the likelihood of warfarin being available for use in the treatment of acute myelogenous leukemia is dim.

Plaintiffs’ attorneys also filed additional new lawsuits in late December, claiming that GlaxoSmithKline knew about the risk of the anticoagulant drugs they sold for decades, yet failed to take measures to mitigate that risk by informing physicians or consumers about the possible adverse effects of these drugs.

Also referred to as anticoagulants, these medicines include such well-known drugs as Warfarin, Ativan, Carafate, and Gemfibrozil, and are designed to prevent clots and break up clogged blood vessels. While these medicines may improve heart health by preventing thrombosis and thereby lowering the risks of strokes and heart attacks, plaintiffs contend that they have suffered long-term and irreversible hair loss, organ and nerve damage, and other consequences attributed to taking these medications. These new lawsuits filed by attorneys and medical groups are currently pending before courts all across the country.

Leave a comment

Your email address will not be published. Required fields are marked *